Uploaded June 2026 | Updated September 2026, 2 weeks ago
Dr. Kristofer Marsh is the Chief Scientific Officer of Smithers Cannabis Testing Services Division, as well the State Director for Smithers’ New York laboratory. He has over 9 years of experience in the Cannabis testing industry spanning operations in 11 U.S. states and is a member of the Cannabis Science Section with the American Council of Independent Laboratories (ACIL).
At CannMed 26, Kris presented “Pyrocannabinoids: An investigation into smoked cannabinoid isolates”
During our conversation, we discuss:
* What pyrocannabinoids are and how they're formed
* Why THCA, CBD, and THCV isolates were chosen as the focus of the study
* What new cannabinoids were created after those isolates were combusted
* How this change in cannabinoids raises questions about the entourage effect in smoked versus ingested cannabis
* Next steps for pyrocannabinoid research
Thanks to This Episode's Sponsor: Cannabis Chemistry Subdivision of the American Chemical Society (CANN)
Since 2015, CANN has been building a strong network of scientists in the cannabis space to promote scientific innovation, safety, and development through education, research, and the empowerment of the scientific community. To learn more about what CANN has to offer please visit their website at www.cann-acs.org.
Additional Resources
Real Isolates - smokenol.com
Smithers - smithers.com/home
Connect with Kris on Linkedin - linkedin.com/in/kristofermarsh
Review the Podcast - podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804
CannMed Archive - cannmedevents.com/cannmed-video-archives
Dr. Kristofer Marsh is the Chief Scientific Officer of Smithers Cannabis Testing Services Division, as well the State Director for Smithers’ New York laboratory. He has over 9 years of experience in the Cannabis testing industry spanning operations in 11 U.S. states and is a member of the Cannabis Science Section with the American Council of Independent Laboratories (ACIL).
At CannMed 26, Kris presented “Pyrocannabinoids: An investigation into smoked cannabinoid isolates”
During our conversation, we discuss:
* What pyrocannabinoids are and how they're formed
* Why THCA, CBD, and THCV isolates were chosen as the focus of the study
* What new cannabinoids were created after those isolates were combusted
* How this change in cannabinoids raises questions about the entourage effect in smoked versus ingested cannabis
* Next steps for pyrocannabinoid research
Thanks to This Episode's Sponsor: Cannabis Chemistry Subdivision of the American Chemical Society (CANN)
Since 2015, CANN has been building a strong network of scientists in the cannabis space to promote scientific innovation, safety, and development through education, research, and the empowerment of the scientific community. To learn more about what CANN has to offer please visit their website at www.cann-acs.org.
Additional Resources
Real Isolates - smokenol.com
Smithers - smithers.com/home
Connect with Kris on Linkedin - linkedin.com/in/kristofermarsh
Review the Podcast - podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804
CannMed Archive - cannmedevents.com/cannmed-video-archives





![Why Explore Cannabinoids as an Alternative to Sleep Medicine for Children with ASD? - Mohsin Maqbool
Why Explore Cannabinoids as an Alternative to Sleep Medicine for Children with Autism Spectrum Disorder (ASD)?
Dr. Mohsin Maqbool is a pediatric neurologist and sleep specialist based in Dallas–Fort Worth, Texas. His work focuses on the intersection of neurodevelopment, sleep, and cannabinoid therapeutics in autism spectrum disorder. He is particularly interested in how cannabinoid formulations may influence sleep regulation, behavior, and quality of life in children with autism.
At CannMed 26, Mohsin will present “Autism, Sleep, and Medicinal Cannabis: Evaluating 18-Month Efficacy and Safety Outcomes”
During our conversation, we discuss:
- The gaps in current sleep medicine for children with Autism Spectrum Disorder
- Results from Mohsin’s 18-month longitudinal study including improvements to total sleep time, sleep onset and maintenance, and overall quality of sleep
- The method of finding the effective dose for each patient
- Cannabinoids’ effect on the duration of REM sleep and what the daytime implications are
- Thinking of cannabis as a tool to supplement conventional ASD medications and not a replacement
- Future research directions - using wearables and EEG to investigate how cannabinoids affect sleep architecture and brain physiology, as well as using biomarkers to see whether patients are a good candidate for cannabinoid therapies
Thanks to This Episode’s Sponsor: The Society of Cannabis Clinicians
The Society of Cannabis Clinicians is a nonprofit professional association of physicians and other healthcare providers. It provides continuing education—for clinicians, patients, and all concerned about the medical use of cannabis and best practices in clinical care. SCC physicians have been monitoring cannabis use by patients for 20 years and have compiled a wealth of clinical evidence and treatment strategies that will be validated by clinical trials in the years ahead.
To learn more about SCC and to join visit cannabisclinicians.org.
Additional Resources
- Effects of Medical Cannabis Treatment for Autistic Children on Family Accommodation: An Open-Label Mixed-Methods Study - https://pmc.ncbi.nlm.nih.gov/articles/PMC12563248/
- [Book] Cannabis Is Medicine: How Medical Cannabis and CBD Are Healing Everything from Anxiety to Chronic Pain by Dr. Bonni Goldstein - https://www.amazon.com/Cannabis-Medicine-Medical-Healing-Everything/dp/031650078X
- Register for CannMed 26 - https://cannmedevents.com/package-options/
- Meet the CannMed 26 Speakers - https://cannmedevents.com/speakers/
- Review the Podcast - https://podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804
- CannMed Archive - https://cannmedevents.com/cannmed-video-archives/ Why Explore Cannabinoids as an Alternative to Sleep Medicine for Children with ASD? - Mohsin Maqbool](https://i.ytimg.com/vi/icACT6YW4Zg/mqdefault.jpg)
![Why is opioid respiratory induced depression a critical target for overdose prevention? - Beth Wiese
Dr. Beth Weise is the Research and Overdose Prevention Coordinator for The Sidewalk Project, a non-profit organization that aids unhoused, drug-using, survivor & sex worker populations by providing direct services including crisis response, system advocacy, wound care, job placement, medication-assisted treatment (MAT), and creative community resources for mental health. Her work aims to influence future drug policy with novel evidence-based research that also advocates and empowers people who use drugs to feel safe and prevent fatal overdose
At CannMed 26, Beth will present Cannabidiol to Mitigate Opioid Induced Respiratory Depression. During our conversation, we discuss:
- What causes Opioid Induced Respiratory Depression and how cannabinoids play a role
- How CBD can be used in combination with Naloxone to reduce withdrawal-related side effects
- How Beth’s research can be applied in real-world scenarios
Thanks to This Episode’s Sponsor: Humanity Heroes
Humanity Heroes provides compassionate support to the unhoused community by delivering essential supplies and resources directly to those in need. Humanity Heroes partners with other nonprofits by empowering them to extend their reach and impact within their own communities. Together, they strive to create a world where every person has access to the resources and support they need to thrive.
Learn more at JoinHumanityHeroes.org
Additional Resources:
- THRRIV.org
- [Webinar] Bridging the Gap: Tech-Supported Peer Connections to Reduce - - Overdose Fatalities - https://www.youtube.com/watch?v=tralDTJlhqs
Register for CannMed 26 - cannmedevents.com Why is opioid respiratory induced depression a critical target for overdose prevention? - Beth Wiese](https://i.ytimg.com/vi/igk2lq5ZNxA/mqdefault.jpg)



